Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $49.97 in the last session, up 2.71% from day before closing price of $48.65. In other words, the price has increased by $2.71 from its previous closing price. On the day, 1.14 million shares were traded. CYTK stock price reached its highest trading level at $50.53 during the session, while it also had its lowest trading level at $48.475.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.28 and its Current Ratio is at 9.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on January 22, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On November 08, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $80.
Goldman Downgraded its Buy to Neutral on August 13, 2024, whereas the target price for the stock was revised from $85 to $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Malik Fady Ibraham sold 2,000 shares for $45.92 per share. The transaction valued at 91,840 led to the insider holds 116,071 shares of the business.
Malik Fady Ibraham sold 2,000 shares of CYTK for $98,640 on Jan 07 ’25. The EVP Research & Development now owns 116,071 shares after completing the transaction at $49.32 per share. On Jan 07 ’25, another insider, FADY MALIK, who serves as the Officer of the company, bought 12,000 shares for $49.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5897159680 and an Enterprise Value of 5793705472. For the stock, the TTM Price-to-Sale (P/S) ratio is 1831.42. Its current Enterprise Value per Revenue stands at 1799.846 whereas that against EBITDA is -11.335.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.83, which has changed by -0.40576524 over the last 52 weeks, in comparison to a change of 0.21794415 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $84.05, while it has fallen to a 52-week low of $44.49. The 50-Day Moving Average of the stock is 2.10%, while the 200-Day Moving Average is calculated to be -8.13%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 1.24M shares per day over the past 3-months and 1228500 shares per day over the past 10 days. A total of 117.89M shares are outstanding, with a floating share count of 113.56M. Insiders hold about 3.77% of the company’s shares, while institutions hold 113.05% stake in the company. Shares short for CYTK as of 1736899200 were 14030843 with a Short Ratio of 11.31, compared to 1734048000 on 13730415. Therefore, it implies a Short% of Shares Outstanding of 14030843 and a Short% of Float of 18.14.
